Gilead Clears Final Hurdle for $7.8B Arcellx Cancer Therapy Deal

FOSTER CITY, CA – April 17, 2026 – Gilead Sciences has successfully navigated the final international regulatory checkpoints for its proposed $7.8 billion acquisition of Arcellx, a pivotal step that brings the biopharmaceutical giant closer to absorbing a highly promising portfolio in cancer treatment. The company announced it has received all necessary approvals, including from Australian and Austrian competition authorities, and has extended its tender offer for Arcellx shares to April 27, 2026.

The move solidifies Gilead’s aggressive strategy to dominate the next generation of cancer therapies, specifically the highly competitive and lucrative market for CAR T-cell treatments. The acquisition gives Gilead full ownership of anitocabtagene autoleucel (anito-cel), an investigational therapy for multiple myeloma that has shown potentially best-in-class efficacy and safety, positioning it as a formidable future competitor in the oncology space.

A Strategic Endgame for Cell Therapy Dominance

This acquisition is the culmination of a multi-year strategic courtship that began as a partnership and has now evolved into a full-scale takeover. In December 2022, Gilead's cell therapy subsidiary, Kite, entered a collaboration with Arcellx to co-develop and co-commercialize anito-cel. The initial deal involved a $225 million upfront payment and a $100 million equity investment, with Arcellx eligible for up to $3.9 billion in milestone payments and a 50/50 profit split in the U.S.

As confidence in anito-cel’s clinical potential grew, Gilead deepened its commitment. A November 2023 expansion of the partnership saw Kite invest another $200 million, increasing its ownership stake to around 13%. The full acquisition, announced in February 2026, represents a strategic pivot from partnership to outright ownership. By taking full control, Gilead eliminates the complex and costly royalty, milestone, and profit-sharing structures, ensuring it reaps the entire financial benefit of anito-cel’s potential market success.

This move aligns perfectly with Gilead's broader ambitions in oncology and its significant financial commitments. The company is already a leader in cell therapy through Kite, which markets the successful CAR T products Yescarta and Tecartus. The addition of Arcellx not only adds a premier asset in anito-cel but also incorporates Arcellx's innovative D-Domain platform technology, which could fuel future therapies for other cancers and even autoimmune diseases. This acquisition is a cornerstone of Gilead's recently announced $32 billion investment plan to expand its U.S. research and manufacturing footprint, signaling a long-term vision to lead in personalized medicine.

The Prize: Anito-cel's Promise in a Crowded Field

The centerpiece of the multi-billion-dollar deal is anito-cel, a CAR T-cell therapy targeting the B-cell maturation antigen (BCMA) to treat relapsed or refractory multiple myeloma. The therapy has garnered significant attention for its remarkable clinical trial results. Data from the Phase 2 iMMagine-1 study, involving 117 heavily pretreated patients, showed an exceptional overall response rate of 97%, with 68% of patients achieving a stringent complete response—a deep and durable remission.

More importantly, 95% of patients achieved minimal residual disease (MRD) negativity, a key indicator of long-term remission. The therapy’s durability is also impressive, with a progression-free survival rate of 66% at 18 months. These figures place anito-cel's efficacy on par with or even exceeding that of Johnson & Johnson’s blockbuster drug, Carvykti, one of two currently approved BCMA CAR T therapies.

However, anito-cel's key competitive advantage may lie in its safety profile. While existing CAR T therapies can be associated with significant side effects like neurotoxicity, anito-cel has demonstrated a more manageable safety record. In the iMMagine-1 study, cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were infrequent and mostly low-grade, with no reports of the delayed neurotoxicity or Parkinsonian-like symptoms that have been a concern for competing products. This favorable safety profile could make anito-cel a preferred option for physicians and patients, potentially allowing for its use in broader patient populations and earlier lines of treatment.

Navigating the Deal's Final Hurdles

With regulatory green lights from the Australian Competition and Consumer Commission and Austrian authorities, the primary remaining condition is the successful completion of the tender offer. Gilead has extended the deadline to 5:00 p.m. Eastern Time on April 27, 2026, to allow remaining shareholders to tender their shares.

The offer consists of $115.00 per share in cash and one contingent value right (CVR). The CVR promises an additional $5.00 per share if cumulative worldwide sales of anito-cel surpass $6.0 billion by the end of 2029—a clause that underscores Gilead’s immense confidence in the drug's blockbuster potential.

As of April 16, approximately 17.5% of Arcellx's outstanding shares had been tendered. While this figure may seem low, it is not uncommon in tender offers for many shareholders, particularly institutional investors and arbitrageurs, to wait until the final days before the deadline to tender their shares. The acquisition remains contingent on a majority of Arcellx's outstanding shares being tendered, a threshold that will be closely watched as the new deadline approaches. With the path now clear of regulatory obstacles, the focus shifts entirely to completing the transaction that could reshape the future of multiple myeloma treatment.